Third-Quarter 2014 Reported Revenues(1) of $12.4 Billion
Third-Quarter 2014 Adjusted Diluted EPS(2) of $0.57, Reported Diluted EPS(1) of $0.42
Repurchased $4.2 Billion of Common Stock to Date in 2014
Updated Ranges for Certain 2014 Financial Guidance Components
NEW YORK, N.Y., Tuesday, October 28, 2014 – Pfizer Inc. (NYSE: PFE) reported financial results for thirdquarter
2014. At the beginning of fiscal year 2014, the company began managing its commercial operations
through a new global commercial structure consisting of three operating segments: the Global Innovative
Pharmaceutical segment (GIP)(3); the Global Vaccines, Oncology and Consumer Healthcare segment (VOC)(3);
and the Global Established Pharmaceutical segment (GEP)(3). Financial results for each of these segments are
presented in the Operating Segment Information section. As a result of the full disposition of Zoetis Inc.
(Zoetis) on June 24, 2013, the financial results of the Animal Health business are reported as a discontinued
operation in the consolidated statements of income for the first nine months of 2013. Some amounts in this
press release may not add due to rounding. All percentages have been calculated using unrounded amounts.
Results are summarized below.
see more on
http://www.pfizer.com/
was niet over te nemen. |